COST-EFFECTIVENESS ANALYSIS OF FILGOTINIB VERSUS TOFACITINIB AS FIRST-LINE TREATMENTS FOR RHEUMATOID ARTHRITIS IN GREECE

被引：0
|
作者：
Nomikos, N. [1 ]
Naoum, P. [1 ]
Athanasakis, K. [1 ]
Kyriopoulos, I [2 ]
机构：
[1] Univ West Attica, Athens, Greece
[2] London Sch Econ & Polit Sci, London, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE134
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [21] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [22] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: A population-level analysis
    Chisholm, D
    EPILEPSIA, 2005, 46 (05) : 751 - 759
  • [24] FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis
    Zhang, Pengfei
    Wen, Feng
    Li, Qiu
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (12) : 1492 - 1497
  • [25] COST-EFFECTIVENESS OF BIOLOGICAL TREATMENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TAIWAN
    Chen, H. F.
    Lin, H. Y.
    Lang, H. C.
    VALUE IN HEALTH, 2012, 15 (07) : A673 - A673
  • [26] Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
    Zrubka, Zsombor
    Gulacsi, Laszlo
    Brodszky, Valentin
    Rencz, Fanni
    Alten, Rieke
    Szekanecz, Zoltan
    Pentek, Marta
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (05) : 537 - 549
  • [27] COST-EFFECTIVENESS OF TOFACITINIB-CONTAINING SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN SPAIN
    Peral, C.
    Navarro, F.
    Montoro, M.
    Balsa, A.
    Gomez, S.
    Pablos, J.
    Martinez-Sesmero, J. M.
    Valderrama, M.
    Oyaguez, I
    de Andres-Nogales, F.
    Casado, M. A.
    VALUE IN HEALTH, 2018, 21 : S296 - S296
  • [28] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN GREECE
    Gourzoulidis, G.
    Solakidi, A.
    Psarra, M.
    Nikitopoulou, E.
    Tzanetakos, C.
    VALUE IN HEALTH, 2023, 26 (12) : S57 - S57
  • [29] Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
    Lee, Min-Young
    Park, Sun-Kyeong
    Park, Sun-Young
    Byun, Ji-Hye
    Lee, Sang-Min
    Ko, Su-Kyoung
    Lee, Eui-Kyung
    CLINICAL THERAPEUTICS, 2015, 37 (08) : 1662 - 1676
  • [30] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Tian, Lei
    Xiong, Xiaomo
    Guo, Qiang
    Chen, Yixi
    Wang, Luying
    Dong, Peng
    Ma, Aixia
    PHARMACOECONOMICS, 2020, 38 (12) : 1345 - 1358
12345